Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16277091 | 0.83 | FAAH (0.45) | FAAHNAMPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL22539971 | 0.81 | FAAH (0.58) | FAAHCASP2NAAAEPHX1 | |
| SCHEMBL21538029 | 0.80 | TDP1 (0.31) | — | |
| SCHEMBL22856128 | 0.73 | MEN1 (0.53) | FAAHMEN1KMT2ACASP2ACHE | |
| SCHEMBL25489116 | 0.73 | NAMPT (0.47) | FAAHNAMPTALDH1A1MEN1KMT2A | |
| SCHEMBL21131782 | 0.72 | LGALS1 (0.43) | ALDH1A1CASP2KDM4ELMNA | |
| SCHEMBL18893543 | 0.72 | EPHX2 (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL15773187 | 0.72 | CYP2C19 (0.38) | FAAHNAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL22790738 | 0.72 | MEN1 (0.52) | FAAHMEN1KMT2ACASP2 | |
| SCHEMBL29978313 | 0.71 | CA3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357656-A1 | Bivalent Ligands for the Treatment of Neurological Disorders | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357656-A1 | Bivalent Ligands for the Treatment of Neurological Disorders | CCR5, OPRM1, OPRK1 | FAAH 1711/4885NAMPT 3174/4885ALDH1A1 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.